SLAMF7 and plasma cell myeloma: Ligation with elotuzumab, a humanized anti-SLAMF7 mAb approved to treat relapsing multiple myeloma (15), promotes NK cells degranulation and IFNγ production after 18h, whereas no significant NK cells activation was observed at 6h of stimulation in HC (Figure 4A).